Radiopharmaceutical company Lantheus Holdings (NASDAQ:LNTH) will be reporting results this Thursday before the bell. Here’s what to look for.
Lantheus beat analysts’ revenue expectations last quarter, reporting revenues of $406.8 million, up 4% year on year. It was a slower quarter for the company, with full-year revenue guidance missing analysts’ expectations significantly and a significant miss of analysts’ full-year EPS guidance estimates.
Is Lantheus a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.
This quarter, the market is expecting Lantheus’s revenue to decline 4.9% year on year, a deceleration from its flat revenue in the same quarter last year.
The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Lantheus has missed Wall Street’s revenue estimates multiple times over the last two years.
Looking at Lantheus’s peers in the healthcare equipment and supplies segment, some have already reported their Q1 results, giving us a hint as to what we can expect. QuidelOrtho’s revenues decreased 10.5% year on year, missing analysts’ expectations by 9.1%, and GE HealthCare reported revenues up 7.4%, topping estimates by 2.1%. GE HealthCare traded down 11.2% following the results.
Read our full analysis of QuidelOrtho’s results here and GE HealthCare’s results here.
There has been positive sentiment among investors in the healthcare equipment and supplies segment, with share prices up 6.5% on average over the last month. Lantheus is up 13% during the same time and is heading into earnings with an average analyst price target of $95.54 (compared to the current share price of $85.78).
WHILE YOU’RE HERE: The Next Palantir? One satellite company captures images of every point on Earth. Every single day. The Pentagon wants it. Hedge funds are using it to beat earnings. You’ve probably never heard of it.
This is what the early days of Palantir looked like before it became a $437 billion giant. Same playbook. Different technology. If you missed Palantir, you need to see this. Claim The Stock Ticker for Free HERE.